Literature DB >> 18460295

Hypertension with metabolic syndrome: think thiazides are old hat? ALLHAT says think again.

Michael D Mendoza1, James J Stevermer.   

Abstract

Entities:  

Year:  2008        PMID： 18460295      PMCID： PMC3183863     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


× No keyword cloud information.
  18 in total

Review 1.  New-onset diabetes and antihypertensive drugs.

Authors:  Giuseppe Mancia; Guido Grassi; Alberto Zanchetti
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  Hussam Abuissa; Philip G Jones; Steven P Marso; James H O'Keefe
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

4.  A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.

Authors:  T Pollare; H Lithell; C Berne
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

Review 5.  The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.

Authors:  G Mancia
Journal:  Acta Diabetol       Date:  2005-04       Impact factor: 4.280

6.  Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.

Authors:  Jürgen Scholze; Elmar Grimm; Dana Herrmann; Thomas Unger; Ulrich Kintscher
Journal:  Circulation       Date:  2007-04-02       Impact factor: 29.690

7.  Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.

Authors:  George Bakris; Mark Molitch; Ann Hewkin; Mark Kipnes; Pantelis Sarafidis; Kaffa Fakouhi; Peter Bacher; James Sowers
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

8.  Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience.

Authors:  Lynn E Eberly; Jerome D Cohen; Ronald Prineas; Lingfeng Yang
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.

Authors:  Monica Gianni; Jackie Bosch; Janice Pogue; Jeffrey Probstfield; Gilles Dagenais; Salim Yusuf; Eva Lonn
Journal:  Eur Heart J       Date:  2007-03-29       Impact factor: 29.983

10.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28
View more
  2 in total

1.  Cardiovascular risk management and its impact on hypertension control in primary care in low-resource settings: a cluster-randomized trial.

Authors:  Shanthi Mendis; S Claiborne Johnston; Wu Fan; Olulola Oladapo; Ali Cameron; Mohammed F Faramawi
Journal:  Bull World Health Organ       Date:  2009-12-08       Impact factor: 9.408

2.  Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.

Authors:  Leopoldo Raij; Brent M Egan; Dion H Zappe; Das Purkayastha; Rita Samuel; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-14       Impact factor: 3.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.